To determine the functional importance of Ras in transformation by Abl oncogenes, we used a genetic approach to measure the effect of impaired Ras activity on the ability of Bcr-Abl or v-Abl to transform cells. Expression of the catalytic domain of the GTPase activating protein for Ras (Gap C terminus) impaired soft agar colony formation by fibroblasts expressing v-Abl 
Summary
To determine the functional importance of Ras in transformation by Abl oncogenes, we used a genetic approach to measure the effect of impaired Ras activity on the ability of Bcr-Abl or v-Abl to transform cells. Expression of the catalytic domain of the GTPase activating protein for Ras (Gap C terminus) impaired soft agar colony formation by fibroblasts expressing v-Abl or Bcr-Abl by 70-80%. To test Ras function in a model that more closely resembles clinical diseases involving Bcr-Abl, double gene retroviruses expressing Bcr-Abl paired with the Gap C terminus or dominant negative Ras were introduced into naive mouse bone marrow cells. Transformation by Bcr-Abl was completely blocked in both situations. Coexpression of normal c-H-Ras accelerated the transforming activity of Bcr-Abl. These findings show that Ras activation is essential for the leukemogenic activity of Abl oncogenes in two distinct model systems. The results genetically define a connection between the Bcr-Abl cytoplasmic tyrosine kinase and Ras and add to the accumulating evidence that deregulation of Ras is a central event in the genesis of a number of molecularly distinct forms of human myeloid leukemia.
T
he Ras family of G-proteins plays a central role in relaying growth stimulatory signals from outside the cell to the nucleus. Mutations in Ras which disrupt this normal signaling pathway lead to deregulated growth and cancer. Surveys of oncogene abnormalities in human leukemia have found a high frequency of activating Ras mutations in acute mydoid leukemias (AML) and myelodysplastic syndromes (MDS), particularly those of the chronic myelomonocytic leukemia (CMML) subtype (1) . Ras mutations are also common in patients with chronic myelogenous leukemia (CML 1) who lack the Bcr-Abl fusion gene (2) . These findings suggest that Ras mutations are a common feature of myeloid leukemias. A notable exception to this trend is the absence of Ras mutations in Bcr-Abl-positive CML (2, 3).
One explanation for this apparent paradox is that Ras is regulated in an abnormal fashion in CML ceils. Ras is activated by stimulatory GDP/GTP exchange molecules such as Sos (4, 5) which convert P, as from its inactive GDP-bound state to its active GTP-bound state. Active Ras can bind and target the cytoplasmic Raf kinase to the cell membrane, where a kinase cascade involving Mek and mitogen-activated protein (MAP) kinase is propagated (6, 7) . Negative control of Ras is mediated by inhibitory GTPase-activating molecules 1 Abbreviations used in this paper: CML, chronic myelogenous leukemia; TK, thymidine kinase. such as RasGap and neurofibromin (NF-1), which convert Ras back to its inactive state.
Philadelphia chromosome-positive CML is characterized by the tumor-spedfic t(9,22) translocation which creates the cytoplasmic Bcr-Abl tyrosine kinase (TK) oncogene. Bcr-Abl transforms fibroblasts and hematopoietic cells in culture and produces leukemias in mice (recently reviewed in 8). Mutational analysis has defined several requirements within BcrAbl for fibroblast transformation. These include on oligomerization domain within Bcr (9), a Grb-2 binding site in Bcr (10) , the SH2 domain (11), a catalytically active kinase domain (12) , the major site of tyrosine autophosphorylation (12) , and an actin binding domain in the Abl COOH terminus (13) . Dominant negative experiments have shown that the c-My: transcription factor is required for Bcr-Abl transformation (14) . A connection between My: and SH2 domain of Bcr-Abl is suggested by the observation that overexpression of c-My: specifically restores transforming activity to the inactive SH2 mutant (11) . The results from complementation experiments such as these define at least two independent pathways required for Bcr-Abl transformation.
Is Ras part of one of these pathways? Studies of the Ras protein in cells expressing Bcr-Abl suggest abnormal levels of activation because a greater than normal proportion of Ras is bound to GTP (15) . Several molecules which can affect Ras activity, such as RasGap (16), Grb-2 (10, 17), Shc (18) , and Crk-L (19), can bind Bcr-Abl. Mutagenesis experiments show a correlation between loss of Grb-2 binding and loss of transforming activity (10) . In this report we have used a genetic approach to evaluate directly if Ras is essential for this transformation signal. Interruption of Ras function by overexpression of the catalytic domain of RasGap or of dominant negative c-H-Ras impairs the transforming activity of Bcr-Abl and v-Abl in fibroblasts and bone marrow cells. The results show that Ras is required for the oncogenic activity of Abl oncogenes and suggest that Ras activity is essential for human CML. Together with the high frequency of activating Ras mutations in AML and MDS, abnormal Ras activity appears to be a common theme in multiple types of human myeloid malignancies.
Materials and Methods
Retroviral Plasmids and Preparation of Virus Stocks. cDNAs encoding the Gap C terminus (provided by Jeff DeClue and Doug Lowy, National Institutes of Health, Bethesda, ME)), c-H-gas and the dominant negative Ash 17 c-H-gas mutant (provided by Simon Cook, Onyx Phamaceuticals, Richmond, CA) were subcloned into the pSRalphaMSVtkNeo retrovirus vector (20) after addition of EcoRI linkers. For bone marrow experiments, the pSRctMSVtkNeo vector was modified to allow simultaneous expression of two genes from a single retrovirus. First, the tkNeo cassette was removed by digestion with ClaI. Secondary HindIlI and ClaI sites in the backbone of the plasmid were destroyed, creating the vector pSRceMSV with unique cloning sites for EcoRI, HindIlI, and ClaI within the LTRs. To provide an internal promoter, the HindIII site was changed to Notl and sequences encoding the TK promoter were subcloned into the Notl site. Gap C terminus, c-H-gas, Ash 17 Ras, or Neo were subcloned into the upstream EcoRl site, and p185 s'-Abl was subcloned into the downstream ClaI site (see Fig. 4 ).
With the exception of v-Mos, all retrovirus stocks were prepared by transient transfection of Cos-7 cell using CaCI2 as described previously (20) . V-mos retrovirus was obtained from a rat-1 fibroblast producer cell line (14) . Transformation Assays. The rat-I/Gap C terminus cell line was generated by infection of rata fibroblasts with helper-free retrovirus followed by selection in G418 (0.5 mg/ml) for 2-3 wk. Cells were maintained continuously in G418 to prevent the outgrowth of cells that might delete the retrovirus construct. Transformation by v-Abl and Bcr-Abl was measured using a soft agar colony assay as described (14) . Hematopoietic cell transformation assays were performed using fresh bone marrow from the tibias and femurs of 4-wk-old BALB/c mice as described previously (21).
Protein Analysis. Expression of the Gap C terminus protein was measured by two-cycle immunoprecipitation of rat-I/Gap C terminus cells Labeled with [3SS]methionine with polyclonal rabbit antisera raised against the full-length Gap protein (kindly provided by Bonnee Rubinfeld, Onyx Pharmaceuticals). Bcr-Abl and v-Abl protein expression was measured by immunoblot or immunohistochemistry using the pex-5 anti-Abl monoclonal antibody (11) .
Results

Overexpression of the Catalytic Domain of RasGap in rat-1
Fibroblasts. Transformation by Abl oncogenes can be quantitatively measured in a single-step soft agar colony assay using rat-1 fibroblasts acutely infected with retroviruses expressing either v-Abl or Bcr-Abl (22) . To determine the role of Ras in this transformation process, we inhibited Ras function by overexpression of the GTPase activating protein for Ras (RasGap), thereby maintaining a greater pool of Ras in the inactive GDP bound state. This approach has been previously used to inhibit the transforming activity of c-H-Ras (23), v-Src (24, 25) , and c-Fms (26) .
cDNAs for the full-length bovine RasGap protein and a truncated form of RasGap (Gap C terminus) containing the catalytic GTPase activating domain but not the NH2-terminal SH2 and SH3 domains, were subcloned into the retrovirus vector pSRotMSVtkNeo (20 (Fig. 1 ). We were unable to derive similar populations overexpressing the full-length RasGap protein despite screening three different G418 populations and 10 independent clones. One explanation for this result might be a toxic effect of constitutive overexpression of full-length RasGap in rat-1 ceils, although overexpression of full-length RasGap has been described in NIH3T3 cells (25) . Importantly, overexpression of the Gap C terminus showed no toxic effects on cell growth. The number of G418 resistant clones recovered after infection with Gap C terminus retrovirus ("ol0S/ml of supernatant) was comparable with control Neo virus of similar titer, and the growth rates of rat-I/Gap C terminus cells and rat-1/Neo were comparable (data not shown).
Overexpression of Gap C Terminus Impairs the Transforming
Activity of Bcr-Abl and v-Abl. To measure the effect of Gap C terminus overexpression on transformation by Abl oncogenes, rat-1/Neo and rat-I/Gap C terminus cells were infected with retroviruses expressing either v-Abl or Bcr-Abl. Retroviruses expressing c-H-Ras, v-Mos, or an empty vector containing only the Neo gene were used as controls. 2 d after infection, cells were plated in soft agar, and transformation was measured by comparing the number of colonies after 2-3 wk.
In three independent experiments, overexpression of the Gap C terminus consistently reduced colony formation by Bcr-Abl and v-Abl by 70-80% (Fig. 2 A) . Photographs of agar plates from a representative assay are shown in Fig. 3 .
rat-1/Neo cells (Fig. 3, top left) and rat-I/Gap C terminus cells (bottom left) failed to form colonies in agar after infection with control Neo retrovirus. After infection with v-A bl retrovirus, rat-1/Neo cells formed numerous large colonies (Fig. 3, top right) whereas rat-I/Gap C terminus cells did not (bottom right). To be sure that both populations were successfully infected with v-Abl retrovirus, anti-Abl immunoblots were performed at the time of the cells were plated in soft agar. The results confirmed equivalent levels of v-Abl protein expression in both populations (data not shown).
We have postulated that the transformation suppression activity of the Gap C terminus is due to downregulation of Ras. If this is the case, then overexpression of the Gap C terminus should impair the transforming activity of normal c-H-Ras. In contrast, the Gap C terminus should not affect the transforming activity of oncogenes known to signal independently of Ras. To test this hypothesis, we infected rat-1/Neo and rat-I/Gap C terminus cells with retroviruses expressing either the normal c-H-Ras gene or the v-Mos serine kinase oncogene, which has been previously shown to transform NIH3T3 cells in a Ras-independent fashion (23, 27) . tion (Fig. 2 A) . These results indicate that rat-I/Gap C terminus cells suppress transformation in a Ras-specific manner and support the hypothesis that the mechanism for this effect is through downregulation of Ras. To be sure that the transformation suppression activity in the rat-I/Gap C terminus cells was due to the Gap C terminus protein and not some other mutation acquired during G418 selection, we repeated the experiment in a fashion that did not require derivation of any cell lines, rat-1 cells were infected simultaneously with two different retrovirus stocks expressing either the Gap C terminus or v-Abl and plated directly into soft agar after 48 h. As previously observed using the rat-I/Gap C terminus cell lines, fewer colonies were seen after simultaneous infection of rat-1 cells with v-Abl and Gap C terminus retroviruses as compared with v-Abl and Neo control retroviruses (Fig. 2 B) . The magnitude of the suppressive effect of the Gap C terminus on v-Abl transformation was lower than with the rat-I/Gap C terminus population because we were unable to introduce the Gap C terminus gene into every cell at risk for v-Abl transformation. TO measure the effect of the Gap C terminus on transformation by Bcr-Abl in this assay, it was critical to ensure that every cell at risk for Bcr-Abl transformation also received a Cap C terminus gene. This experiment required simultaneous introduction of Bcr-Abl and the Gala C terminus gene into the same cell using a single retrovirus system. To accomplish this, the Bcr-Abl and Gap C terminus cDNAs were cloned into a vector previously developed by us for studies of BcrAbl and dominant negative Myc (14) . 
Overexpression of Gap C Impairs the Transforming
Dominant Negative Ras Inhibits, Whereas Wild-type Ras Stimulates Bone Mamau Transformation by Bcr-Abl.
In addition to its role as a negative regulator of Ras, RasGap may also act as a downstream effector of Ras (28) . Therefore, it is possible that the suppressive effect of the Gap C terminus on Bcr-Abl transformation might result from interference with a Ras effector pathway. To address this issue, we inhibited Ras function by a different strategy, using a dominant inhibitory Ras mutant containing a serine to asparagine mutation at position 17 (Asn 17 Ras) (27) . This mutant shows preferential a~nity for GDP over GTP due to improper Mg 2+ binding and presumably acts as a competitive inhibitor of normal Ras by binding to guanine nucleotide exchange factors (29) . The murine bone experiments described above were repeated using either normal c-H-Ras or the dominant negative Asn 17 Ras paired with Bcr-Abl in the two gene retrovirus system. 
Discuuion
Studies of a number of different receptor and cytoplasmic TKs show a correlation between Ras activation and mitogenic activity (30) . However, there have been relatively few direct tests of the requirement for Ras for biological activity (31) . For the Bcr-Abl TK, biochemical studies show an devated ratio of active GTP-Ras versus GDP-Ras in cells expressing Bcr-Abl (15) . A Bcr-Abl mutant which fails to activate transcription from a Ras-responsive reporter construct in NIH3T3 calls cannot transform rat-1 fibroblasts (10) . Although data such as these support a correlation between Ras activation and transforming activity by Bcr-Abl, they fail to directly test the requirement for Ras in transformation.
In this work we have used a genetic approach to demonstrate directly that Ras is required for the transforming activity of Bcr-Abl. We have impaired Ras function in fibroblasts and in hematopoietic calls using two strategies that affect different sides of the Ras regulatory cycle. Overexpression of the COOH terminal GTPase activating domain of RasGap impairs Ras activity by converting active GTP-bound Ras to inactive GDP-bound Ras. The result is a higher than normal percentage of Ras in the GDP-bound state. The dominant inhibitory Asn 17 Ras mutant acts as a competitive inhibitor of normal Ras for binding to GDP/GTP exchange molecules, thereby preventing normal Ras activation. In both cases, transformation by Bcr-Abl is suppressed.
Our findings are consistent with a recent report (32) showing that the growth of a CML cell line expressing BcrAbl is impaired by antisense oligonucleotides directed against Ras. One interpretation of these results is that inhibition of Ras leads to generalized growth suppression rather than a specific effect on the Bcr-Abl transformation signal. In fact the Ash 17 Ras mutant, which is widely used by a number of groups to impair Ras activity, is known to suppress normal growth in fibroblasts (27) . Our studies of the Gap C ter-minus mutant in nontransformed cells show that this is not the case. High level expression of Gap C terminus showed no toxic effects on cell growth in fibroblasts or hematopoietic cells (our unpublished observations). The suppressive activity of the Gap C terminus on transformation was specific because it did not impair the transforming activity of a Rasindependent gene, v-Mos.
Our findings suggest that Bcr-Abl activates an essential signaling pathway that flow through Ras. Recent biochemical experiments showing Bcr-Abl binds to Grb-2 (10, 17) provide a potential mechanism for a Bcr-Abl connection to Ras. Whether Grb-2 is the critical connection to Ras is not clear. Although a Bcr-Abl molecule with a mutation of the Grb-2 binding site (Y177) is no longer able to transform rat-1 fibroblasts, it does have growth stimulatory activity in hematopoietic cells (Goga, A., D. Afar, J. McLaughlin, C. Sawyers, and O. Witte, unpublished observations). These findings indicate there may be additional pathways from BcrAbl to Ras, perhaps through other adaptor molecules known to.bind Bcr-Abl such as Shc (18) or Crk-L (19) . The recent identification of interactions between c-Abl and the Crk SH3 domain provides a potential mechanism for such a pathway (33, 34) .
In addition to Ras, Myc is another protein essential for transformation by Bcr-Abl (14) . How do Ras and Myc fit together in the Bcr-Abl transformation pathway? Complementation experiments show that overexpression of oMyc specifically restores transforming activity to a Bcr-Abl gene rendered inactive due to a mutation in the phosphotyrosine binding region of its SH2 domain (11) . These experiments define a Myc pathway and suggest that the SH2 domain is responsible for a signal to Myc, perhaps through its promoter. If the Grb-2 binding site in Bcr-Abl is indeed the primary connection to Ras, the fact that Myc does not complement a Grb-2 binding mutant of Bcr-Abl may indicate that Ras and Myc act independently. Further complementation analysis is required to sort out these issues.
Our findings support accumulating evidence that Ras deregulation is a common theme in many types of human myeloid leukemia. In AML, MDS, and Bcr-Abl negative CML, point mutations in Ras are common and create a constitutively active protein. Molecular studies of myeloid leukemias which are not associated with Ras mutations, are beginning to uncover abnormalities in Ras regulation. Leukemia cells from children with juvenile CML, a disease which phenotypically resembles adult CML but is not associated with a Bcr-Abl translocation or with Ras mutations, contain mutations in both alleles of NF-I (35) . Similar to RasGap, NF-1 is a negative regulator of Ras. Loss of function should lead to abnormal Ras activation. Our results suggest that Ras activation is also abnormal in adult CML because of constitutive activation by Bcr-Abl. Through a similar mechanism, it appears likely that the fusion protein in patients with t(5,12) associated CMML may also activate Ras. This translocation fuses the platelet-derived growth factor receptor (PDGFR-B) to a novel gene called Tel (36) . Structural characteristics predict a receptor TK which is no longer regulated by binding to its ligand.
